Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in operable breast cancer patients with hormone receptor-positive, HER2-negative - Scorecard - MDSpire

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in operable breast cancer patients with hormone receptor-positive, HER2-negative

  • By

  • Yirui Wei

  • Mengyuan Wang

  • Yong Huang

  • Lu Gan

  • Kangjie Li

  • Yifeng Li

  • Zhaoyang Li

  • Qiao Cheng

  • May 8, 2026

  • 0 min

Share

Clinical Scorecard: Comparative Analysis of Long-Term Survival in Operable Hormone Receptor-Positive, HER2-Negative Breast Cancer Patients Receiving Neoadjuvant versus Adjuvant Chemotherapy

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationFemale patients aged 20–70 with unilateral invasive HR+/HER2- breast cancer at stage II and T3N1M0.
Care Setting

Key Highlights

  • HR

Guideline-Based Recommendations

Diagnosis

  • Consider NACT for tumors larger than T2 or with lymph node involvement (CSCO, updated 2023).
  • Preoperative systemic therapy preferred for clinically node-positive disease (NCCN, updated 2023).

Management

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Female patients aged 20–70 with unilateral invasive HR+/HER2- breast cancer.

        Patients undergoing both chemotherapy and surgery, with no distant metastasis at diagnosis.

        Clinical Best Practices

        • Utilize propensity score matching for comparative analysis to minimize bias.
        • Consider individual patient factors such as age, comorbidities, and tumor characteristics when selecting chemotherapy type.

        Related Resources & Content

        Original Source(s)

        Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in operable breast cancer patients with hormone receptor-positive, HER2-negative

        • by Yirui Wei, Mengyuan Wang, Yong Huang, Lu Gan, Kangjie Li, Yifeng Li, Zhaoyang Li, Qiao Cheng

        • May 8, 2026

        Related Content

        Successful reversal of hepatic visceral crisis in HER2-positive metastatic breast cancer: a case report

        New Mammography Screening Guidance: Clinical Considerations for Risk-Based Care

        New guidance from the American College of Physicians (ACP) recommends biennial mammography screening for average-risk women ages 50 to 74.

        • by

        • May 26, 2026

        • 5 min
        Longitudinal predictor analysis of pain in breast cancer survivors on aromatase inhibitors—the PAC-WOMAN trial